2017 HALF YEAR RESULTS

Transforming our portfolio in H1

_



+ MeadJohnson



Completed acquisition of Mead Johnson

- A global leader in infant formula and children's nutrition
- The company's Enfa family of brands, including Enfamil infant formula, is the world's leading franchise
- Back office synergies to be implemented earlier than expected

\$17.9 billion Total value of the acquisition, including MJN's net debt

Disposal of Food business

- Agreed sale of non-core, but high quality business to McCormick
- Allows greater focus on consumer health brands
- Proceeds to be used to reduce debt

\$4.2 billion

- Price received by RB
- √ 7.4 times 2016 sales
- → 20.4 times EBITDA

83% of portfolio* is now Health and Hygiene

83%

Health & Hugiene

17% Home

2020 target hit two years earlier than anticipated

and we're



in Consumer Health Care

including Infant Formula and Child Nutrition

2017 HALF YEAR RESULTS

Positioned for growth in H2

Full year target +2% LFL* net revenue growth





H1 £3,189m (-3% LFL*) Q2 £1,520m (-4% LFL*) Q2 £833m (+2% LFL*)

H1 E1,702m (+3% LFL*)

Q2 revenue £2,479m -2% LFL*



Performance impacted by recent cyber-attack New measures implemented to strengthen IT systems

MeadJohnson

H1 (-3%) and H2 target (-2% – flat)

Underlying business is strong, driven by innovation



Broad-based arowth across most consumer brands, with performance supported by robust product innovation pipeline, particularly aimed at key developing markets





* Like-for-like net revenue growth excludes the impact of changes in exchange rates, acquisitions, disposals and discontinued operations.

This document provides a high level summary of the Reckitt Benckiser Group's quarterly results statement only, and is not a substitute for reading the full statement. For more information and a copy of the complete 2017 H1 Results Statement, please visit www.RB.com